Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 349

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 349
---
 amounting to $ 645,693in exchange for the Company’s forgiveness of a $ 600,000shortfall in the exercise price of the Series A Preferred Warrants that was unpaid. In December 2024, the Investor exercised its Series A Preferred Warrants to purchase shares of Series A Preferred stock of the Company for which such investor remitted a partial exercise price amount of $ 100,000instead of the exercise price of $ 700,000. During the three months ended September 30, 2024, 7,005shares of Series A Preferred Stock were converted into 54,474shares of Common Stock. During the nine months ended September 30, 2025, 1,090shares of Series A Preferred Stock were converted into 14,447shares of Common Stock. The conversion ratio was based on the Series A Certificate of Designations and reflected the application of the Alternate Conversion Price described above, applicable as of each date of conversion plus a 25% premium for penalties due. As a result of the 25% premium, during the nine months ended September 30, 2025, the Company recorded the following: 1) for 473shares of Series A Preferred Stock converted during the continuance of a Trigger Event as described above, the Company recorded a deemed dividend of $ 118,250, which represents the fair value of excess common stock convertible and issuable to the preferred shareholders upon occurrence of the trigger event based on an average per share common share price of $ 95.00, the effect of which was an increase in the net loss attributable to common shareholders in the accompanying condensed consolidated statement of operations for the nine months ended September 30, 2025, and 2) for 625shares of Series A Preferred Stock converted after the expiration of a Trigger Event as described above, the Company recorded a stock-based inducement expense of $ 156,250, which represents the fair value of excess common stock transferred to the preferred shareholders based on an average per share common share price of $ 95.00and is reflected as part of other income (expense), net, on the accompanying condensed consolidated statement of operations for the nine months ended September 30, 2025. Additionally, during the three and nine months ended September 30, 2025, Series C Preferred Stock was converted by investors at a conversion price lower than the conversion price of the Series A Preferred Stock then in effect. The lower conversion price lowered the Series A Preferred Stock conversion price from $